Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för GSK343. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

10 träffar

Bibliografisk träff 2020-03-25

GSK343, an inhibitor of EZH2, mitigates fibrosis and inflammation mediated by HIF-1α in human peritoneal mesothelial cells treated with high glucose.

Wang Q, Xu L, Zhang X, Liu D, Wang R.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2020.173076

Bibliografisk träff 2019-10-25

GSK343 induces programmed cell death through the inhibition of EZH2 and FBP1 in osteosarcoma cells.

Xiong X, Zhang J, Li A, Dai L, Qin S, Wang P, Liu W, Zhang Z, Li X, Liu Z.

Cancer Biol Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1080/15384047.2019.1680061

Bibliografisk träff 2019-10-01

p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma.

Yang PM, Hong YH, Hsu KC, Liu TP.

Am J Cancer Res · research-article; journal article

Bibliografisk träff 2019-08-02

GSK343 induces autophagy and downregulates the AKT/mTOR signaling pathway in pancreatic cancer cells.

Xu H, Zhang L, Qian X, Zhou X, Yan Y, Zhou J, Ge W, Albahde M, Wang W.

Exp Ther Med · research-article; journal article · DOI 10.3892/etm.2019.7845

Bibliografisk träff 2018-10-26

Inhibition of histone methyltransferase EZH2 in Schistosoma mansoni in vitro by GSK343 reduces egg laying and decreases the expression of genes implicated in DNA replication and noncoding RNA metabolism.

Pereira ASA, Amaral MS, Vasconcelos EJR, Pires DS, Asif H, daSilva LF, Morales-Vicente DA, Carneiro VC, Angeli CB, Palmisano G, Fantappie MR, Pierce RJ, Setubal JC, Verjovski-Almeida S.

PLoS Negl Trop Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pntd.0006873

Bibliografisk träff 2017-11-02

(-)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells.

Ying L, Yan F, Williams BR, Williams BR, Xu P, Li X, Zhao Y, Hu Y, Wang Y, Xu D, Dai J.

Clin Exp Pharmacol Physiol · journal article · DOI 10.1111/1440-1681.12854

Bibliografisk träff 2017-09-27

The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells.

Yu T, Wang Y, Hu Q, Wu W, Wu Y, Wei W, Han D, You Y, Lin N, Liu N.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.21311

Bibliografisk träff 2017-06-01

[Therapeutic effect of enhancer of Zeste homolog 2 inhibitor GSK343 on periodontitis by regulating macrophage differentiation].

Zhongchao W, Liyuan F, Dan T, Cong Z, Shijun L.

Hua Xi Kou Qiang Yi Xue Za Zhi · research-article; journal article · DOI 10.7518/hxkq.2017.03.007

Bibliografisk träff 2016-05-27

Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells.

Xiong X, Zhang J, Liang W, Cao W, Qin S, Dai L, Ye D, Liu Z.

Int J Oncol · journal article · DOI 10.3892/ijo.2016.3541

Bibliografisk träff 2016-01-29

In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes.

Liu TP, Hong YH, Tung KY, Yang PM.

Oncoscience · research-article; journal article · DOI 10.18632/oncoscience.285